财富增长最快的公司之全明星

Celgene生物制药公司

2012年排名： 91

连续上榜时间：4年

    完成几宗大手笔收购后，这家总部位于新泽西州萨米特的生物制药公司在2011年继续保持增长。Celgene2009年首次上榜，排名第22。此后，该公司每年都跻身“财富增长最快的公司排行榜”，努力成为肿瘤医疗行业的领头羊。

    Celgene治疗血液和骨髓疾病的热销药Revlimid 和Vidaza取得了巨大的成功，继续推动公司大踏步发展。2011年，公司营业收入同比增长34%，达到了约48亿美元。

    但公司也遇到了一些挫折。该公司一直在争取让血癌药Revlimid能在欧洲扩大使用范围，但最近撤回了申请，令投资者十分意外。这种药物已经在欧洲和美国获准用于治疗多发性骨髓瘤，但Celgene一直在寻求将这种药物更早地提供给骨髓瘤患者，并将它作为维持疗法。

Celgene

2012 Fastest-Growing rank: 91

Years on list: 4

    Coming off a few major acquisitions, the Summit, NJ-based biopharmaceutical company continued to gain in 2011. Celgene first made it onto this list in 2009, coming in at No. 22. Since then, it has continued to be among the Fortune's fastest growing companies every year as the company works to become an oncology leader.

    Celgene continued winning with the successes of popular drugs Revlimid and Vidaza for blood and bone marrow conditions. For 2011, revenues rose by 34% to approximately $4.8 billion over the previous year.

    The company has seen some setbacks, however. It has been trying to win approval in Europe to widen use of blood cancer drug Revlimid, but withdrew its application recently in a move that stunned investors. The drug is already approved in Europe and the U.S. to treat multiple myeloma, but Celgene has been seeking to offer the treatment sooner to myeloma patients and as a maintenance therapy.